Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

By D. Black, P. Delmas, Richard Eastell, I. Reid, S. Boonen, J. Cauley, F. Cosman, P. Lakatos, P. Leung, Z. Man and 11 more. New England Journal of Medicine, 2007

2,601 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/39fe8b2ad13e0e207c6af396e6d7bedfcd846fd8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. R. Russell
2. Chris Cooper
3. R. Rizzoli
4. J. Reginster
5. on behalf of the International Osteoporosis Foundation
6. J. Kanis
7. R. Baron
8. S. Ferrari

In Oncology

1. R. Russell
2. J. Reginster
3. J. Kanis
4. Chris Cooper
5. R. Rizzoli
6. on behalf of the International Osteoporosis Foundation
7. S. Ferrari
8. Richard Eastell

In Orthopedics and Sports Medicine

1. Chris Cooper
2. J. Reginster
3. J. Kanis
4. R. Rizzoli
5. R. Russell
6. on behalf of the International Osteoporosis Foundation
7. S. Ferrari
8. Richard Eastell

Citations in the corpus

• Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards (2011, neutral): “Zoledronate Black [97] 5 mg/year i.”
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “fractures by 70% and that of hip fractures by 40% [224] and is now available for the treatment of postmenopausal osteoporosis.”
• Bisphosphonates: the first 40 years. (2011, background): “then, risedronate [209,210], ibandronate [211], and most recently zoledronate [212].”
• The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT) (2011, methodology): “In the core study, there had been significant differences in acute phase response between the ZOL and placebo groups, particularly after the first infusion.((1,24)) In the extension, rates of postdose symptoms were much lower than active group rates in the core study and not significantly different ”
• Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (2008, methodology): “Zoledronate [104] NED [104] [104] [104] NED”
• Denosumab and bisphosphonates: different mechanisms of action and effects. (2011, background): “relative risk reduction, respectively [101,154,157–159].”
• KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) (2017, methodology): “For example, in an RCTof zoledronic acid for the treatment of postmenopausal osteoporosis, bALP levels were 59% lower in the zoledronic acid group compared with the placebo group at 12 months.(33)”